A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions
Authors:
- 8 November 2017
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 32 (5) , 783-790
Abstract
Background: Dermatology Life Quality Index (DLQI) is the most common health‐related quality of life measure in dermatology that is widely used in treatment guidelines for psoriasis. Eight of the 10 questions of the DLQI offer a ‘not relevant’ response (NRR) option that is scored as the item had no impact on patients’ life at all.Objective: To explore the occurrence of NRRs on the DLQI in psoriasis patients and to examine the effect of several socio‐demographic and clinical factors on giving NRRs.Methods: Data were obtained from two cross‐sectional surveys among psoriasis patients at two academic dermatology clinics in Hungary. Health‐related quality of life was measured by employing DLQI and EQ‐5D‐3L, while disease severity was graded by Psoriasis Area and Severity Index (PASI). Multivariate logistic regression was applied to determine the predictors of providing NRRs.Results: Mean age of the 428 patients was 49 years, and 65% were males. Mean PASI, DLQI and EQ‐5D‐3L index scores were 8.4 ± 9.5, 6.8 ± 7.4 and 0.74 ± 0.28, respectively. Overall, 38.8% of the patients had at least one NRR: 19.6% (one), 11.5% (two), 5.1% (three) and 2.6% (more than three). Most NRRs occurred in sport, sexual difficulties and working/studying items of the DLQI (28.4%, 16.4% and 14.0%, respectively). Female gender (OR 1.65; 95% CI 1.04–2.61), older age (OR 1.05; 95% CI 1.03–1.07) and higher PASI score (OR 1.03; 95% CI 1.01–1.06) were associated with providing more NRRs, whereas highly educated patients (OR 0.34; 95% CI 0.16–0.72) and those with a full‐time job (OR 0.47; 95% CI 0.29–0.77) less frequently tended to tick NRRs.Conclusion: The high rate of psoriasis patients with NRRs, especially among women, less educated and elderly patients, indicates a content validity problem of the measure. A reconsideration of the use of the DLQI for medical and financial decision‐making in psoriasis patients is suggested.Keywords
This publication has 62 references indexed in Scilit:
- Psychometric properties of the Chinese version of dermatology life quality index (DLQI) in 851 Chinese patients with psoriasisJournal of the European Academy of Dermatology and Venereology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- Evaluation of the reimbursement criteria for biological therapies for psoriasis in the NetherlandsBritish Journal of Dermatology, 2008
- Financial deficits in the health services of the UK and HungaryThe Lancet, 2006
- Psychometric Properties of the Dermatology Life Quality Index (DLQI) in 900 Italian Patients with PsoriasisActa Dermato-Venereologica, 2005
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005
- Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of lifeAnnals of Allergy, Asthma & Immunology, 2004
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990